Latigo Bio's commercial strategy is not to completely replace opioids but to relegate them to a last-resort option for rare and extreme situations. This pragmatic approach acknowledges that pain is treated multimodally and positions their Nav1.8 drug as the primary, safer alternative for the vast majority of patients, reducing overall opioid dependency.
Beyond the risk of addiction, the widespread prescription of opioids creates other major problems. These include gastrointestinal side effects like constipation and nausea, as well as the societal risk of leftover pills being stolen, sold, or accidentally used by children. This broader problem statement fortifies the argument for safer alternatives like Nav1.8 inhibitors.
Latigo Bio sees the market entry of competitor Vertex's Nav1.8 drug not as a threat, but as a crucial step in market creation. Vertex's launch educates physicians and patients about a completely new class of pain medicine for the first time in decades, creating awareness and demand that a follower company like Latigo can then capitalize on with a potentially 'best-in-class' product.
Instead of a one-size-fits-all product, Latigo is creating two distinct Nav1.8 drugs. One offers rapid onset for acute pain (as a BID, or twice-a-day, drug), while the other is a once-daily (QD) formulation better suited for chronic pain management where adherence and convenience are key. This demonstrates a nuanced product-market fit strategy.